• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Allogene Therapeutics, Inc. - Common Stock (NQ:ALLO)

    2.390 +0.020 (+0.84%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Apr 17, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 11,548,757
    Open 2.400
    Bid (Size) 2.370 (3,900)
    Ask (Size) 2.380 (200)
    Prev. Close 2.370
    Today's Range 2.340 - 2.530
    52wk Range 0.8621 - 4.460
    Shares Outstanding 142,183,418
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock
    From Allogene Therapeutics, Inc.
    Via GlobeNewswire
    Thursday's session: gap up and gap down stocks ↗
    Via Chartmill

    Performance

    YTD
    +77.0%
    +77.0%
    1 Month
    +11.2%
    +11.2%
    3 Month
    +46.6%
    +46.6%
    6 Month
    +94.3%
    +94.3%
    1 Year
    +64.8%
    +64.8%

    More News

    Read More
    News headline image
    Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases
    From Allogene Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Allogene Therapeutics Announces Pricing of Public Offering of Common Stock
    From Allogene Therapeutics, Inc.
    Via GlobeNewswire
    Allogene Therapeutics Inc (NASDAQ:ALLO) Reports Narrower-Than-Expected Q4 Loss, Highlights Key 2026 Clinical Catalysts ↗
    Via Chartmill
    News headline image
    JPMorgan, Allogene Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock
    From Allogene Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    These stocks are making the most noise in today's session. ↗
    Via Chartmill
    News headline image
    ENDRA Life Sciences (NASDAQ: NDRA) Targets Billions With TAEUS® Liver Imaging Technology
    Via AB Newswire
    News headline image
    Allogene Therapeutics Stock Hits 52-Week High - Here's Why ↗
    Via Benzinga
    News headline image
    These stocks are gapping in today's session ↗
    Via Chartmill
    News headline image
    Leggett & Platt, Allogene Therapeutics, Revolution Medicines And Other Big Stocks Moving Higher On Monday ↗
    Via Benzinga
    Topics Stocks
    News headline image
    Which stocks are moving before the opening bell on Monday? ↗
    Via Chartmill
    News headline image
    Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL
    From Allogene Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Get insights into the top gainers and losers of Friday's after-hours session. ↗
    Via Chartmill
    News headline image
    Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026
    From Allogene Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Allogene (ALLO) Q4 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update
    From Allogene Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update
    From Allogene Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
    From Allogene Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Stock Market Today, Jan. 21: ImmunityBio Rises Again As Short-Sellers Face Losses ↗
    Via The Motley Fool
    Topics Stocks
    News headline image
    The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff
    From Equity Insider
    Via GlobeNewswire
    The market is filled with gapping stocks in Friday's session. ↗
    Via Chartmill
    News headline image
    Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T
    From Allogene Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Billionaire Family Office Dumps All of Its UroGen Stock Amid 100% Rally ↗
    Via The Motley Fool
    Topics Death Regulatory Compliance

    Frequently Asked Questions

    Is Allogene Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Allogene Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Allogene Therapeutics, Inc. - Common Stock trade on?
    Allogene Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Allogene Therapeutics, Inc. - Common Stock?
    The ticker symbol for Allogene Therapeutics, Inc. - Common Stock is ALLO on the Nasdaq Stock Market
    What is the current price of Allogene Therapeutics, Inc. - Common Stock?
    The current price of Allogene Therapeutics, Inc. - Common Stock is 2.390
    When was Allogene Therapeutics, Inc. - Common Stock last traded?
    The last trade of Allogene Therapeutics, Inc. - Common Stock was at 04/17/26 04:00 PM ET
    What is the market capitalization of Allogene Therapeutics, Inc. - Common Stock?
    The market capitalization of Allogene Therapeutics, Inc. - Common Stock is 339.82M
    How many shares of Allogene Therapeutics, Inc. - Common Stock are outstanding?
    Allogene Therapeutics, Inc. - Common Stock has 340M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.